Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases
Public ClinicalTrials.gov record NCT02215512. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases (BRAINSTORM)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
In this dose-escalation study, the safety and tolerability of escalating dose levels of RRx-001 administered intravenously twice a week in subjects with brain metastases receiving whole brain radiation therapy (WBRT) will be assessed. Once a maximum tolerated dose is identified, further (up to approximately 30) participants will be recruited. The study will use MRI to monitor changes in tumor blood flow associated with RRx-001.
Study identification
- NCT ID
- NCT02215512
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 29 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 5, 2015
- Primary completion
- Nov 27, 2016
- Completion
- Nov 11, 2020
- Last update posted
- Nov 2, 2021
2015 – 2020
United States locations
- U.S. sites
- 5
- U.S. states
- 4
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Providence Saint John's Health Center | Santa Monica | California | 90404 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Allegiance Health | Jackson | Michigan | 49201 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| The Cancer Institute of New Jersey (Rutgers University) | New Brunswick | New Jersey | 08903 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Brain Metastases trials
Other public records listing Brain Metastases. Sorted by last update posted; newest first. Not a recommendation.
- NCT04073966: MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly Diagnosed Brain Mets Recruiting
- NCT07248228: Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial) Recruiting
- NCT02886585: Pembrolizumab In Central Nervous System Metastases Active, not recruiting
- NCT03726359: Phase I Study of Fractionated Stereotactic Radiation Therapy Active, not recruiting
- NCT03223922: Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases Active, not recruiting
- NCT05419076: A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02215512, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 2, 2021 · Synced Sep 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02215512 live on ClinicalTrials.gov.